The importance of SOCS1 − 1478 CA/del polymorphism and expression in breast cancer: a case–control study in the north of Iran

Paeiz, Habibbullah; Salehi, Zivar; Mashayekhi, Farhad; Saeidi Saedi, Hamid; Mirzanejad, Laleh

doi:10.1007/s10549-023-07070-3

Cited by 3 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A polymorphism in the SOCS1 promoter region (-1478 CA>del) has been reported to increase SOCS1 expression in atopic asthma (127), and has been associated with breast and gastric cancer, as well as with a poorer outcome in colon cancer (128)(129)(130)(131). The effect of this polymorphism remains unclear, although it does not appear to be linked to tumor suppression.…”

Section: Socs1 Is Linked To Tumor Suppressionmentioning

confidence: 99%

SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity

Bidgood,

Keating,

Doggett

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

The Suppressor of Cytokine Signaling (SOCS) family proteins are important negative regulators of cytokine signaling. SOCS1 is the prototypical member of the SOCS family and functions in a classic negative-feedback loop to inhibit signaling in response to interferon, interleukin-12 and interleukin-2 family cytokines. These cytokines have a critical role in orchestrating our immune defence against viral pathogens and cancer. The ability of SOCS1 to limit cytokine signaling positions it as an important immune checkpoint, as evidenced by the detection of detrimental SOCS1 variants in patients with cytokine-driven inflammatory and autoimmune disease. SOCS1 has also emerged as a key checkpoint that restricts anti-tumor immunity, playing both a tumor intrinsic role and impacting the ability of various immune cells to mount an effective anti-tumor response. In this review, we describe the mechanism of SOCS1 action, focusing on the role of SOCS1 in autoimmunity and cancer, and discuss the potential for new SOCS1-directed cancer therapies that could be used to enhance adoptive immunotherapy and immune checkpoint blockade.

show abstract